托-金林途径中的代谢物与炎症性肠病之间的关联:两样本的孟德尔随机化
Fangqian Yu1, Yutong Du1, Cong Li1
1The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
Scientific reports
|January 3, 2024
概括
这项研究发现,托芬 (TRP) 对炎症性肠病 (IBD) 有保护作用. 相反,金氨酸 (KYN) 显著增加患IBD及其亚型,性结肠炎和克罗恩病的风险.
科学领域:
- 代谢学 代谢学 代谢学
- 遗传学 遗传学 是一个
- 胃肠病学 胃肠病学
背景情况:
- 观察性研究表明,托 (TRP) - 氨酸 (KYN) 途径与炎症性肠病 (IBD) 之间存在联系.
- TRP-KYN代谢物和IBD之间的因果关系仍然不确定.
- 了解这种关系对于IBD的发病和治疗至关重要.
研究的目的:
- 研究关键TRP-KYN途径代谢物对IBD及其亚型的潜在因果影响.
- 用强大的遗传方法区分关联和因果关系.
主要方法:
- 采用了两个样本的门德尔随机化 (MR) 研究设计.
- 利用了TRP和KYN作为暴露和IBD作为结果的全基因组关联研究 (GWAS) 的总结数据.
- 逆方差加权 (IVW) 方法是主要分析,补充了MR-Egger,加权模式,简单模式和加权中位数方法.
主要成果:
- 卜素 (TRP) 显示出与IBD (OR 0.739,95% CI [0.697; 0.783]),性结肠炎 (UC) (OR 0.875,95% CI [0.814; 0.942]) 和克罗恩病 (CD) (OR 0.685,95% CI [0.613; 0.765]) 有着显著的保护性关联.
- 基努瑞宁 (KYN) 被确定为IBD (OR 4.406,95% CI [2.247; 8.641]),UC (OR 2.578,95% CI [1.368; 4.858]) 和CD (OR 13.516,95% CI [4.919; 37.134]) 的重要危险因素.
结论:
- 门德尔的随机化分析支持托在IBD中的因果保护作用.
- 基努瑞宁因果关系与IBD及其亚型的风险增加有关.
- 这些发现凸显了TRP-KYN通路作为IBD的潜在治疗点.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Irritable Bowel Syndrome I: Introduction
277
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
277
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128
Inflammatory Bowel Disease I: Ulcerative Colitis
187
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
187
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
140
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
140
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166


